Returns | 1W : 0.5% , 1M : 0.4%,1Y : 50.6% |
LT :   |
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Average |
ST :   |
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Peers & Returns | 1W | 1M | 1Y |
DR REDDYS LABORATORIES LTD | 0.5% | 0.4% | 50.6% |
SUN PHARMACEUTICAL INDUSTRIES LTD | 2.4% | 2.4% | 64.7% |
DIVIS LABORATORIES LTD | 3.7% | 0.5% | 66.9% |
CIPLA LTD | 0.4% | -1.2% | 102.3% |
BIOCON LTD | 1.2% | 2.8% | 38.6% |
AUROBINDO PHARMA LTD | 2% | -4.5% | 75.3% |
LUPIN LTD | 3.7% | 2.7% | 64.9% |
TORRENT PHARMACEUTICALS LTD | 1.3% | -2.9% | 14.9% |
CADILA HEALTHCARE LTD | 1.8% | -4.7% | 69.6% |
Ratio | Value |
---|---|
P/E P/B P/S |
36.92
P/E Calculated based on EPS of 121.9
[ Mar2020 - Consolidated Results ] 4.83
P/B Calculated based on Book Value of 932.31
[ Mar2020 - Consolidated Results ] 4.14
P/S Calculated based on Revenues of 18085.3 Cr
[ TTM - Consolidated Results ] |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
108% 33% 37% |
Pledged Shares |
0 % |
---|---|
As on : Sep2020 | |
If less than 25% | Good |
If between 25% and 50% | Neutral |
If greater than 50% | Bad |